Perhaps Colombia scientists have found a global antiviral

The world of immune in Colombia Dosan Bogunovich has discovered the antiviral forces for individuals about 15 years ago, shortly after determining the genetic mutation that causes the condition.

Initially, the condition seemed only to increase weakness in some bacterial infections. But with more patients identifying, its unexpected antiviral benefits have become clear. Bogonovich, a professor of immunology at children at the Faggos College at the University of Fellaus at the University of Colombia, quickly learned that everyone suffers from a mutation, which causes a deficiency in the immune regulator called ISG15, who suffers from a mild but continuous system.

“The type of inflammation that had antivirals was when it emerged that these individuals could hide something,” Bogonovich recalls. When he and his colleagues looked at the immune cells of individuals, they can see confrontations with all types of viruses – influenza, measles, mumps, chickenpox. But patients have not reported any public signs of infection or disease.

“In the back of my mind, I kept thinking that if we were able to produce this type of light immunodeficiency in others, we can protect them from almost any virus,” says Bogonovich.

Today, Bogunovic closes a therapeutic strategy that can provide widespread protection against viruses and become an important weapon in the next epidemic.

At the end of his studies, published on August 13 in Science medicineBogunovic and his team have informed that the experimental therapy they developed is given to the recipients temporarily (hamster and mice, so far) is the same as the great antiviral power like people with ISG15 deficiency. When administered preventive in animal lungs by nasal drip, prevent viral repetition of influenza virus and SARS-COV-2 and the severity of the disease.

In cell culture, “we have not yet found a virus that could penetrate the reasons for treatment,” says Bogunovic.

Simulation of the Great Immunology of a rare case

Bogunovic treatment is designed to imitate what is happening in people with ISG15 deficiency, but only for a short period.

Instead of turning off the ISG15 directly – which leads to the production of more than 60 proteins – the therapeutic Bogunovic turns on the production of 10 proteins responsible primarily for broad antiviral protection.

The current design is similar to Covid MRNA vaccines, but with the development of: Ten MRNAS Coding Ten Proteins are filled within the sebaceous nanoparticles. Once the nanoparticles are absorbed by the recipient’s cells, cells generate the ten host proteins for the production of antiviral protection.

“We only generate a small amount of these ten proteins, for a very short period, and this leads to a much lower inflammation than we see in individuals with ISG15 deficiency,” says Bogonovich. “But this inflammation is sufficient to prevent antiviral diseases.”

The basis of future treatment

Bogunovic believes that their technology is a weapon for the next epidemic – which provides protection for the first respondents and people in the care homes and family members of the injured individuals – regardless of the responsible virus.

“We believe that technology will work even if we do not know the identity of the virus,” says Bogonovich. More importantly, the antiviral protection provided by technology will not prevent people from developing their immune memory into the virus for long -term protection.

But the properties of delivery of medications and technology absorption still need improvement. When they are delivered to animals via nanoparticles, the ten proteins were produced in the lungs, “but it may not be at high levels enough to make us comfortable to enter people immediately,” says Bogunovich.

“Once the treatment reaches our cells, it works, but connecting any DNA, DNA or RNA, to part of the body you want to protect is the biggest challenge in this field.” Researchers also need to determine the duration of antiviral protection for treatment, which is currently three to four days.

“The results we have reached enhances the force of the research driven by curiosity without prior concepts,” says Bogonovich. “We were not looking for an antiviral when we started studying our rare patients, but studies inspired the potential development of global antivirals for all.”

The study was published, “The study of the petition based on the ISG15 deficiency, from the viral infection in the laboratory and in the live body”, August 13 in Science medicine.

All authors: YEMPROCT T Sinai), Rachel Geelson (Columbat Sina), Ashley HHARD RHAMARD RHAMARD SIAI, Martin Fernandez (Colombia and De Saloud Carlos III), Christos Siziids (Colombia and Mountain Sinai), Rebecca L. Pearl (Mountain Sina), McCaimri Mays (Mount Sinai), Andrew B. Corland (Colombian and Mount D. García-SASTRE (Mount Sinai), Brad R. Rosenberg (Mount Sinai), and Bogunovic (COOMBIA).

This research has been supported by grants and contracts from the National Institute of Allergy and Infectious Diseases (R01ai151029, R01Ai127372, R41AI164999, R21Ai134366, R21Ai129827, R01Ai150837, R01AI124690, T32ai07647, T32aii U19ai135972, 75n93021c00014); Dimat march. Department of Microbiology, ICAHN College of Medicine in the Mount Sinai Fund; The Grant HR0011-19-2-319 0020.

Dusan Bogunovic reports in Lab11 Therapeutics.